Skip to main content
USA News
  2020-10-13
MASON, Ohio --(BUSINESS WIRE)--Oct. 13, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020 .
  2020-09-01
MASON, Ohio --(BUSINESS WIRE)--Sep. 1, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global
  2020-08-06
MASON, Ohio --(BUSINESS WIRE)--Aug. 6, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal
  2020-07-29
MASON, Ohio --(BUSINESS WIRE)--Jul. 29, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences.
  2020-07-28
Worldwide revenue of $40.8 million – a decrease of 30.7% year over year U.S. revenue of $33.7 million – a decrease of 28.6% year over year International revenue of $7.1 million – a decrease of 39.0% year over year MASON, Ohio --(BUSINESS WIRE)--Jul. 28, 2020-- AtriCure, Inc.
  2020-07-07
MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020 .
  2020-05-11
MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to
  2020-05-11
MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell
  2020-05-08
Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure MASON, Ohio --(BUSINESS WIRE)--May 8, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)
  2020-04-30
MASON, Ohio --(BUSINESS WIRE)--Apr. 30, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m.
  2020-04-29
Worldwide revenue of $53.2 million – a decrease of 1.4% year over year U.S. revenue of $43.5 million – an increase of 1.1% year over year International revenue of $9.8 million – a decrease of 11.0% year over year MASON, Ohio --(BUSINESS WIRE)--Apr. 29, 2020-- AtriCure, Inc.
  2020-04-27
MASON, Ohio --(BUSINESS WIRE)--Apr. 27, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences.
  2020-04-15
MASON, Ohio --(BUSINESS WIRE)--Apr. 15, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020 .
  2020-04-13
MASON, Ohio --(BUSINESS WIRE)--Apr. 13, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the
  2020-04-09
MASON, Ohio --(BUSINESS WIRE)--Apr. 9, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to